Section
The OCULUS randomized trial demonstrates that continuing GLP-1/GIP agonists before upper endoscopy significantly increases the risk of clinically significant residual gastric volume compared to holding a single dose, providing crucial evide
A randomized clinical trial demonstrates that a 15% dose increase allows levothyroxine to be taken with breakfast without compromising TSH stability, significantly improving patient preference and well-being.
This review synthesizes population-level data on the eligibility for GLP-1RAs, SGLT2is, and nsMRAs, highlighting that over 60% of US adults meet indications for these transformative therapies.
A large multicohort study involving 11,319 participants confirms that Coronary Artery Calcium (CAC) scoring effectively stratifies cardiovascular risk even in individuals with high Lipoprotein(a), providing clinical clarity for personalized
This article explores a groundbreaking study identifying CRLF1, a protein secreted by cardiac fibroblasts, as a key driver of Hypertrophic Cardiomyopathy (HCM). This paracrine signaling mechanism offers a potential universal therapeutic tar
This article outlines new expert consensus on conducting rigorous qualitative research in internal medicine, providing a roadmap for investigators to move beyond numbers and capture the human experience of healthcare through methods like in
This review evaluates the evidence for prophylactic haemostasis during endobronchial biopsy, centered on the PROTECT trial results, while integrating contemporary data on procedural safety, pre-procedural screening, and technical optimizati
A randomized clinical trial indicates that neither metformin nor ursodeoxycholic acid (UDCA) significantly improves recovery from postacute sequelae of SARS-CoV-2 (PASC) compared to placebo, highlighting the ongoing challenge of finding eff
The Phase 3 GRACE trial demonstrates that relacorilant, a selective glucocorticoid receptor modulator, significantly maintains hypertension control in patients with Cushing’s syndrome without the safety concerns associated with non-selectiv
New research identifies TRIM28 as a critical E3 ubiquitin ligase that degrades IRP2, thereby suppressing iron uptake and preventing myocardial ferroptosis during ischemia/reperfusion injury. This pathway, activated by p55γ and the drug perh
This article details the SCORE2-HF risk model, a newly validated tool designed to estimate 10-year and 30-year heart failure risks in asymptomatic individuals, enabling earlier intervention and personalized cardiovascular care across divers
This clinical update synthesizes evidence on Roseburia inulinivorans, identifying it as a species-specific gut microbe that enhances muscle strength by modulating amino acid metabolism and skeletal muscle fiber types.
This review explores the development of WUSTL0717, a gut-restricted LXR agonist that mitigates liver injury in short bowel syndrome by leveraging the intestinal HDL-ApoA1 pathway without inducing systemic metabolic complications.
A longitudinal study of 2,260 participants confirms that oral glucose tolerance test (OGTT)-based surrogate indexes, particularly Gutt and Cederholm, are superior to fasting-only measures in predicting type 2 diabetes, providing high clinic
This phase 2 trial demonstrates that varenicline, a partial nAChR agonist, significantly reduces premature ventricular complexes and nonsustained ventricular tachycardia in post-myocardial infarction patients, offering a novel therapeutic t
A breakthrough study demonstrates that high-intensity interval training (HIIT) significantly enhances mitochondrial cristae density and surface area in men with type 2 diabetes, revealing remarkable plasticity in muscle ultrastructure despi
This large retrospective study of 820 patients reveals that restrictive ventricular physiology is the most common phenotype in cardiac amyloidosis. While preserved LV function offers better initial survival, the rate of progression to restr
The multicentre GOULASH trial reveals that high-energy nutrition in the early phase of acute pancreatitis does not improve outcomes and may increase risks of organ failure and pain relapse compared to a gradual caloric increase, leading to
A massive cohort study of 245,388 US adults reveals that 1 in 287 carries a familial hypercholesterolemia mutation. Despite high risks for premature heart disease, most carriers remain undertreated, with fewer than 20% of those with establi
The ACHIEVE-3 phase 3 trial demonstrates that orforglipron, a novel non-peptide oral GLP-1 receptor agonist, provides superior glycemic control compared to oral semaglutide in adults with type 2 diabetes, despite a higher frequency of gastr
